Brief: Zymeworks' Zanidatamab Approved in China for HER2-High Expression Biliary Tract Cancer

Zymeworks

30/05/2025 11:17

May 30 (Reuters) - Zymeworks Inc ZYME.O:

ZYMEWORKS ANNOUNCES NMPA APPROVAL OF ZANIDATAMAB IN CHINA FOR ADULTS WITH PREVIOUSLY TREATED, UNRESECTABLE OR METASTATIC HER2-HIGH EXPRESSION (IHC3+) BILIARY TRACT CANCER

ZYMEWORKS INC - TO RECEIVE $20 MILLION MILESTONE PAYMENT FROM BEONE MEDICINES

ZYMEWORKS INC - ELIGIBLE FOR UP TO $144 MILLION IN ADDITIONAL MILESTONES

ZYMEWORKS INC - ELIGIBLE FOR UP TO 19.5% ROYALTIES ON NET SALES

Source text: ID:nGNX1bMvZx

Further company coverage: ZYME.O

 ((Reuters.Briefs@thomsonreuters.com;))